Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of lenalidomide plus R-ICE in relapsed/refractory non-GCB DLBCL after R-CHOP
ChiCTR1800016724Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, rituximab, ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: overall response rate. Started Jul 2018; status: recruiting.
02
Drugs
lenalidomiderituximabifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1800016724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016724.